289 related articles for article (PubMed ID: 25963298)
41. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
42. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
43. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
44. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.
Sutton LA; Rosenquist R
Haematologica; 2015 Jan; 100(1):7-16. PubMed ID: 25552678
[TBL] [Abstract][Full Text] [Related]
45. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
46. Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Del Poeta G; Gaidano G; Rossi FM; Zucchetto A; Gattei V
Semin Hematol; 2014 Jul; 51(3):168-76. PubMed ID: 25048781
[TBL] [Abstract][Full Text] [Related]
47. Next-generation sequencing in chronic lymphocytic leukemia.
Villamor N; López-Guillermo A; López-Otín C; Campo E
Semin Hematol; 2013 Oct; 50(4):286-95. PubMed ID: 24246696
[TBL] [Abstract][Full Text] [Related]
48. Chronic lymphocytic leukaemia genomics and the precision medicine era.
Ghamlouch H; Nguyen-Khac F; Bernard OA
Br J Haematol; 2017 Sep; 178(6):852-870. PubMed ID: 28444740
[TBL] [Abstract][Full Text] [Related]
49. Molecular pathogenesis of CLL and its evolution.
Rodríguez D; Bretones G; Arango JR; Valdespino V; Campo E; Quesada V; López-Otín C
Int J Hematol; 2015 Mar; 101(3):219-28. PubMed ID: 25630433
[TBL] [Abstract][Full Text] [Related]
50. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Landau DA; Carter SL; Stojanov P; McKenna A; Stevenson K; Lawrence MS; Sougnez C; Stewart C; Sivachenko A; Wang L; Wan Y; Zhang W; Shukla SA; Vartanov A; Fernandes SM; Saksena G; Cibulskis K; Tesar B; Gabriel S; Hacohen N; Meyerson M; Lander ES; Neuberg D; Brown JR; Getz G; Wu CJ
Cell; 2013 Feb; 152(4):714-26. PubMed ID: 23415222
[TBL] [Abstract][Full Text] [Related]
51. Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia.
Bagnara D; Mazzarello AN; Ghiotto F; Colombo M; Cutrona G; Fais F; Ferrarini M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430731
[TBL] [Abstract][Full Text] [Related]
52. Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.
Dal Bo M; Bomben R; Zucchetto A; Del Poeta G; Gaidano G; Deaglio S; Efremov DG; Gattei V
Curr Pharm Des; 2012; 18(23):3323-34. PubMed ID: 22591383
[TBL] [Abstract][Full Text] [Related]
53. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies.
Gunnarsson R; Mansouri L; Rosenquist R
Leuk Lymphoma; 2013 Aug; 54(8):1583-90. PubMed ID: 23167608
[TBL] [Abstract][Full Text] [Related]
54. Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment.
Frenzel LP; Reinhardt HC; Pallasch CP
Oncol Res Treat; 2016; 39(1-2):9-16. PubMed ID: 26889681
[TBL] [Abstract][Full Text] [Related]
55. Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
Kittai AS; Lunning M; Danilov AV
Curr Hematol Malig Rep; 2019 Aug; 14(4):302-309. PubMed ID: 31049852
[TBL] [Abstract][Full Text] [Related]
56. CD38 and chronic lymphocytic leukemia: a decade later.
Malavasi F; Deaglio S; Damle R; Cutrona G; Ferrarini M; Chiorazzi N
Blood; 2011 Sep; 118(13):3470-8. PubMed ID: 21765022
[TBL] [Abstract][Full Text] [Related]
57. Mutations driving CLL and their evolution in progression and relapse.
Landau DA; Tausch E; Taylor-Weiner AN; Stewart C; Reiter JG; Bahlo J; Kluth S; Bozic I; Lawrence M; Böttcher S; Carter SL; Cibulskis K; Mertens D; Sougnez CL; Rosenberg M; Hess JM; Edelmann J; Kless S; Kneba M; Ritgen M; Fink A; Fischer K; Gabriel S; Lander ES; Nowak MA; Döhner H; Hallek M; Neuberg D; Getz G; Stilgenbauer S; Wu CJ
Nature; 2015 Oct; 526(7574):525-30. PubMed ID: 26466571
[TBL] [Abstract][Full Text] [Related]
58. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.
Schuh A; Becq J; Humphray S; Alexa A; Burns A; Clifford R; Feller SM; Grocock R; Henderson S; Khrebtukova I; Kingsbury Z; Luo S; McBride D; Murray L; Menju T; Timbs A; Ross M; Taylor J; Bentley D
Blood; 2012 Nov; 120(20):4191-6. PubMed ID: 22915640
[TBL] [Abstract][Full Text] [Related]
59. Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
Playa-Albinyana H; Arenas F; Royo R; Giró A; López-Oreja I; Aymerich M; López-Guerra M; Frigola G; Beà S; Delgado J; Garcia-Roves PM; Campo E; Nadeu F; Colomer D
Leukemia; 2024 Mar; 38(3):557-569. PubMed ID: 38017105
[TBL] [Abstract][Full Text] [Related]
60. Descriptive analysis of genetic aberrations and cell of origin in Richter transformation.
Chitalia A; Swoboda DM; McCutcheon JN; Ozdemirli M; Khan N; Cheson BD
Leuk Lymphoma; 2019 Apr; 60(4):971-979. PubMed ID: 30632835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
